Sangamo Therapeutics (SGMOQ) Change in Acquisitions & Divestments (2010 - 2024)

Sangamo Therapeutics' Change in Acquisitions & Divestments history runs 15 years deep, the most recent figure standing at -$33.6 million for Q3 2024.

• On a quarterly basis, Change in Acquisitions & Divestments changed N/A year-over-year to -$33.6 million in Q3 2024; TTM through Jun 2025 was -$33.6 million, a 161.73% decrease from a year earlier, with the FY2024 full-year figure at $1.1 million, down 94.38% from the prior year.
• Change in Acquisitions & Divestments retreated to -$33.6 million in Q3 2024 per SGMOQ's latest filing, from $34.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $314.6 million in Q4 2020 and bottomed at -$252.7 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $84.4 million (2022), against an average of $58.8 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 222.84% in 2021 and plunged 370.98% in 2022, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $314.6 million in 2020, then plunged by 70.35% to $93.3 million in 2021, then plunged by 370.98% to -$252.7 million in 2022, then jumped by 107.81% to $19.7 million in 2023, then plunged by 270.34% to -$33.6 million in 2024.
• Per Business Quant, the three latest SGMOQ Change in Acquisitions & Divestments figures stand at -$33.6 million (Q3 2024), $34.7 million (Q1 2024), and $19.7 million (Q4 2023).